Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296346 · ClinicalTrials.gov registry record · NA
Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
A NA study, sponsored by University of Utah.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT02296346: Clinical Trial NA study, sponsored by University of Utah.
NCT02296346 is a NA study that was terminated before completion, run by University of Utah. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296346, a NA study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
In this research study, the investigators will determine whether a procedure called Extracorporeal Photopheresis (ECP) is helpful in preventing progression of disability in people with SPMS when compared to monthly corticosteroid infusions. This study will determine whether ECP has an effect on inflammatory cells in people with SPMS and whether it has a beneficial therapeutic effect.
Primary Outcome
MSFC score is a composite score calculated from 3 tests: 1) Timed 25-Foot walk (leg function); 2) 9-Hole Peg Test (arm function); and 3) Paced Auditory Serial Addition Test (cognitive function). The results are combined to create a single score (the MSFC Z-Score) to measure performance and change over time in subjects with MS. MSFC Z-score = {Z arm + Z leg + Z cognitive} / 3.0. A positive score indicates that, on average, an individual performed better than the reference population and a negativ
Interventions
- DRUG SoluMedrol
- DEVICE Extracorporeal Photopheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-05-10 |
| Phase | NA |
Why NCT02296346 stopped before completion
NCT02296346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which SoluMedrol is the first listed.
NCT02296346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02296346 about?
NCT02296346 is a clinical study titled "Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis". In this research study, the investigators will determine whether a procedure called Extracorporeal Photopheresis (ECP) is helpful in preventing progression of disability in people with SPMS when compared to monthly corticosteroid infusions. This study will determine whether ECP has an effect on infl...
What is the current status of trial NCT02296346?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2014-10. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT02296346?
The interventions under investigation include: SoluMedrol (DRUG), Extracorporeal Photopheresis (DEVICE).
Who is sponsoring clinical trial NCT02296346?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02296346's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia